<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04698265</url>
  </required_header>
  <id_info>
    <org_study_id>KSVGH20-CT9-11, ASA RCT 1.0</org_study_id>
    <nct_id>NCT04698265</nct_id>
  </id_info>
  <brief_title>Efficacy of Intra-articular Injection of Human Amniotic Suspension Allograft and Platelet-rich Plasma in the Treatment of Knee Osteoarthritis.</brief_title>
  <official_title>Comparison of the Efficacy of Intra-articular Injection of Human Amniotic Suspension Allograft and Platelet-rich Plasma in the Treatment of Knee Osteoarthritis: A Prospective, Double-blind, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Veterans General Hospital.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, randomized controlled trial designed to evaluate the symptomatic modulating&#xD;
      efficacy of amniotic suspension allograft (ASA) in comparison to platelet-rich plasma (PRP),&#xD;
      hyaluronic acid (HA) and normal saline (NS) in the injection treatment of knee&#xD;
      osteoarthritis. The hypothesis is that ASA would provide the greatest functional improvement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At least 150 subjects with osteoarthritic knee will be recruited and computer randomized&#xD;
      1:1:1:1 to single injection of ASA (40mg), ASA (20mg), PRP + HA, and NS groups. Both subjects&#xD;
      and evaluaters were blinded to allocations. Functional and radiologic outcomes were measured&#xD;
      at baseline, and 1 week, 1, 3, 6, 12 months postinjection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the Western Ontario and McMaster Universities Arthritis Index (WOMAC) between baseline, 1 week, and 1 ,3 ,6 ,12 months.</measure>
    <time_frame>Baseline, 1 week, 1,3,6,12 months</time_frame>
    <description>WOMAC is a self-administered questionnaire consisting of 24 items divided into 3 subscales:(1) Pain (5 items): during walking, using stairs, in bed, sitting or lying, and standing upright(2) Stiffness (2 items): after first waking and later in the day(3) Physical Function (17 items): using stairs, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy domestic duties, light domestic dutiesThe test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the International Knee Documentation Committee (IKDC Questionnaire) between baseline, 1 week, and 1 ,3 ,6 ,12 months.</measure>
    <time_frame>Baseline, 1 week, 1,3,6,12 months</time_frame>
    <description>The International Knee Documentation Committee Questionnaire is a knee-specific patient-reported outcome measure.The questionnaire looks at 3 categories: symptoms, sports activity, and knee function. The symptoms subscale helps to evaluate things such as pain, stiffness, swelling and giving-way of the knee. Meanwhile, the sports activity subscale focuses on functions like going up and down the stairs, rising from a chair, squatting and jumping. The knee function subscale asks patients one simple question: how is their knee at present versus how was their knee prior to injury? Scores are obtained by summing the individual items, then transforming the crude total to a scaled number that ranges from 0 to 100, This final number is interpreted as a measure of function with higher scores representing higher levels of function.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Knee Osteoarthristis</condition>
  <arm_group>
    <arm_group_label>Human amniotic suspension allograft (ASA), 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human amniotic suspension allograft (ASA) contains particulated human amniotic membrane and cells derived from the amniotic fluid. The allograft is freeze-dried, terminally sterilized with low dose gamma irradiation. Arm 1 uses 40 mg ASA stored in a sterile vial (Amniogen, HTC Regenerative Ltd. New Taipei, Taiwan).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Human amniotic suspension allograft (ASA), 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human amniotic suspension allograft (ASA) contains particulated human amniotic membrane and cells derived from the amniotic fluid. The allograft is freeze-dried, terminally sterilized with low dose gamma irradiation. Arm 2 uses 20 mg ASA stored in a sterile vial (Amniogen, HTC Regenerative Ltd. New Taipei, Taiwan).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CellularMatrix (a combination of platelet-rich plasma and hyaluronic acid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CellularMatrix (RegenLab SA, Switzerland) is composed of sterile and non-pyrogenic tubes allowing the mix of Platelet Rich Plasma (PRP) with Hyaluronic Acid (HA) in the same proportion (2mL of PRP for 2mL of HA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4ml of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human amniotic suspension allograft (ASA)</intervention_name>
    <description>Human amniotic suspension allograft (ASA) intra-articular injection.</description>
    <arm_group_label>CellularMatrix (a combination of platelet-rich plasma and hyaluronic acid)</arm_group_label>
    <arm_group_label>Human amniotic suspension allograft (ASA), 20 mg</arm_group_label>
    <arm_group_label>Human amniotic suspension allograft (ASA), 40 mg</arm_group_label>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 20 and 80 years&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Unilateral or bilateral knee VAS pain score ≥ 4 of 10 (worst possible pain) for more&#xD;
             than 4 months&#xD;
&#xD;
          -  Diagnosis of OA Kellgren-Lawrence I-III by radiography (triple-film of bilateral lower&#xD;
             limb, standard knee anterior-posterior view in full extension, lateral view in&#xD;
             30-degrees flexion, and 45°Merchant views)&#xD;
&#xD;
          -  No prior PRP injection of knee&#xD;
&#xD;
          -  No prior surgical procedure of the participating knee&#xD;
&#xD;
          -  BMI&lt;40 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lawrence stage IV&#xD;
&#xD;
          -  Major axial deviation (varus&gt; 5°, valgus &gt; 5°)&#xD;
&#xD;
          -  Any concomitant symptomatic knee disorder (i.e. ligamentous/ meniscal injury)&#xD;
&#xD;
          -  Systemic inflammatory arthropathy&#xD;
&#xD;
          -  Hematologic diseases&#xD;
&#xD;
          -  Severe cardiovascular disease&#xD;
&#xD;
          -  Neurological disorders&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Immuno-compromised&#xD;
&#xD;
          -  Therapy with anticoagulants or antiaggregants&#xD;
&#xD;
          -  Use of NSAIDs and/or chondroprotective supplements, such as glucosamines and&#xD;
             chondroitin sulfates, within 7 days prior to trial&#xD;
&#xD;
          -  Recent intra-articular injection of corticosteroids (within 30 days)&#xD;
&#xD;
          -  Prior treatment with HA in past 6 monthsHb&lt; 11 g/dL&#xD;
&#xD;
          -  Platelet count &lt; 150,000/mm3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kuan-Yu Lin</last_name>
    <phone>+886-7-3422121</phone>
    <phone_ext>3051</phone_ext>
    <email>johnkyl@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yin-Ming Huang</last_name>
    <phone>+886-7-3422121</phone>
    <phone_ext>3051</phone_ext>
    <email>rex781104@hotmail.com</email>
  </overall_contact_backup>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 20, 2020</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Veterans General Hospital.</investigator_affiliation>
    <investigator_full_name>Yin Ming, Huang</investigator_full_name>
    <investigator_title>Chief resident of Orthopedic.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We do not have the plan to make individual participant data (IPD) available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

